Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Trachtenberg

Showing results (101-110 of 136) with videos related to

Pageof 14
Sort By:
AJR. American Journal of Roentgenology|July 24, 2015
Real-Time MRI-Guided Focused Ultrasound for Focal Therapy of Locally Confined Low-Risk Prostate Cancer: Feasibility and Preliminary OutcomesSangeet Ghai, Alyssa S Louis, Meghan Van Vliet, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 11, 2014
Health-related quality of life following radical prostatectomy: long-term outcomesAndrew G Matthew, Shabbir M H Alibhai, Tal Davidson, et al.
International Journal of Cancer|January 6, 2011
Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progressionLiyang Liu, Ken J Kron, Vaijayanti V Pethe, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|March 10, 2010
DNA methylation of HOXD3 as a marker of prostate cancer progressionKen J Kron, Liyang Liu, Vaijayanti V Pethe, et al.
BJU International|May 21, 2014
Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapyCaroline M Moore, Abel-Rahmene Azzouzi, Eric Barret, et al.
European Urology|March 30, 2010
Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracyUri Lindner, Nathan Lawrentschuk, Robert A Weersink, et al.
BJU International|May 23, 2008
Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light dosesJohn Trachtenberg, Robert A Weersink, Sean R H Davidson, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 25, 2003
Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancerRobert K Nam, William W Zhang, John Trachtenberg, et al.
European Radiology|April 27, 2018
Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trialSangeet Ghai, Nathan Perlis, Uri Lindner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2006
Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsyRobert K Nam, William W Zhang, Laurence H Klotz, et al.
Pageof 14

Showing results (101-110 of 136) with videos related to

Sort By:
Pageof 14
AJR. American Journal of Roentgenology|July 24, 2015
Real-Time MRI-Guided Focused Ultrasound for Focal Therapy of Locally Confined Low-Risk Prostate Cancer: Feasibility and Preliminary OutcomesSangeet Ghai, Alyssa S Louis, Meghan Van Vliet, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 11, 2014
Health-related quality of life following radical prostatectomy: long-term outcomesAndrew G Matthew, Shabbir M H Alibhai, Tal Davidson, et al.
International Journal of Cancer|January 6, 2011
Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progressionLiyang Liu, Ken J Kron, Vaijayanti V Pethe, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|March 10, 2010
DNA methylation of HOXD3 as a marker of prostate cancer progressionKen J Kron, Liyang Liu, Vaijayanti V Pethe, et al.
BJU International|May 21, 2014
Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapyCaroline M Moore, Abel-Rahmene Azzouzi, Eric Barret, et al.
European Urology|March 30, 2010
Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracyUri Lindner, Nathan Lawrentschuk, Robert A Weersink, et al.
BJU International|May 23, 2008
Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light dosesJohn Trachtenberg, Robert A Weersink, Sean R H Davidson, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 25, 2003
Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancerRobert K Nam, William W Zhang, John Trachtenberg, et al.
European Radiology|April 27, 2018
Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trialSangeet Ghai, Nathan Perlis, Uri Lindner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2006
Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsyRobert K Nam, William W Zhang, Laurence H Klotz, et al.
Pageof 14